A5 Labs Signs Partnership Agreement for the Production of Interferon Products
MONTREAL, QUEBEC--(Marketwire - October 26, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced the signing of a binding agreement with a European-based Institute of Microbiology for the production of interferon products. The Institute has agreed to manufacture natural source interferon products using A5 Labs' proprietary production technology. The production of interferon finished products at the Institute will represent an important step in validation of A5 Labs' production technology. Subsequently, A5 Labs plans to submit the products manufactured at the institute for in-vitro and in-vivo testing according to USP (United States Pharmacopaeia) guidelines at multi-centered independent laboratories.
The agreement was drafted following the meetings between the respective managements of A5 Labs and the Institute during the last week of September 2010.
"We are extremely pleased to sign this partnership agreement with such a prestigious Institute. This is a highly significant milestone which will provide a leap forward towards the commercialization of our natural source interferon products. Following the laboratory and scale up production of our products we will immediately begin our veterinary trials and submission of our application for human clinical trials," said Dr. Richard Azani, President and CEO.
More information about the Company is available at its corporate website at www.a5labs.com.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "plan", "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 and specifically to its plans to produce its products and subject them to trials, identify forward-looking statements. Such forward-looking statements as are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.